导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.12% | 722/4773 |
| 近一周 | 0.95% | 782/5467 |
| 近一月 | -9.54% | 4354/5421 |
| 近一季 | -13.68% | 3902/5238 |
| 近半年 | 14.79% | 475/4931 |
| 近一年 | 16.25% | 672/4400 |
| 近两年 | 164.77% | 166/2954 |
| 近三年 | 121.13% | 81/2253 |
| 成立以来 | 55.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.15% 4047/4961 |
52.45% 537/5312 |
- - |
- - |
| 2025 | 64.98% 150/4813 |
5.16% 813/3635 |
1.47% 2317/4076 |
54.86% 203/4524 |
-0.15% 2386/4813 |
| 2024 | 20.16% 486/3463 |
-1.79% 1280/2808 |
-2.52% 1199/3014 |
14.36% 1993/3129 |
9.75% 308/3463 |
| 2023 | 13.19% 52/2656 |
37.14% 44/2280 |
-2.40% 588/2385 |
-13.11% 2133/2515 |
-2.68% 513/2655 |
| 2022 | -33.10% 1696/2207 |
-19.29% 1442/1919 |
-3.48% 1822/2016 |
-19.77% 1811/2113 |
7.03% 332/2208 |
| 2021 | - - |
- - |
- - |
- - |
10.66% 98/1822 |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 天弘中证人工智能A VS. 长安沪深300非周期A(740101) |